BioGaia’s oral health probiotics to be launched in Hong Kong
BioGaia has signed an exclusive agreement with BioWellTech Co Ltd for the rights to sell BioGaia ProDentis in Hong Kong. The launch is planned to take place during the third quarter of 2016.
BioWellTech Co Ltd was established in 2011 and is already one of the leading dental equipment distributors in Hong Kong. The company focuses on licensing, business development, marketing, sales and distribution of a wide range of dental implants and peripheral products for dental professionals. BioWellTech has an experienced sales team with established relationships with dental and medical professionals.
“Dental implantation is well accepted in Hong Kong and the market has grown very fast during the past five years. As BioGaia ProDentis prohibits the growth of pathogens and thus contributes to the stability of the implant after surgery, we are confident that, with the commitment of our strong sales and marketing team, the product will become a success in Hong Kong”, says Vincent Chau, Director, BioWellTech Co Ltd.
“BioGaia ProDentis as an adjunct in the management of patients with implants is a promising new indication. With BioWellTech we have a strong and experienced local partner within this area and we therefore hope for a successful launch of BioGaia ProDentis in Hong Kong”, says Axel Sjöblad, Managing Director, BioGaia.
Latest press releases from BioGaia
2016-04-06 Notice to attend the Annual General Meeting at BioGaia AB
2016-03-18 Extraordinary General Meeting of BioGaia
2016-03-18 Meta-analysis confirms effectiveness of BioGaia ProDentis in periodontitis
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 25 April 2016, 09:00 am CET.
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com